期刊
NPJ PRECISION ONCOLOGY
卷 1, 期 -, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41698-017-0005-2
关键词
-
类别
资金
- Ludwig Institute for Cancer Research
- NIH grant [NS73831]
- Defeat GBM Program of the National Brain Tumor Society
- Ben and Catherine Ivy Foundation
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073831] Funding Source: NIH RePORTER
The cancer genome provides the blueprint for identifying oncogenic mutations driving tumor growth and these mutant proteins and pathways are the targets for precision cancer therapies. However, many oncogenes are capable of reprogramming the landscape of active portion of the genome, commonly known as the epigenome. This creates fluidity, and thereby heterogeneity, that demands consideration of this additional layer of complexity for effective therapeutic design and application. Molecular dissection of the epigenome may identify oncogene-induced, actionable vulnerabilities, broadening the spectrum of precision oncology treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据